Mar. 25 at 3:53 PM
$ALDX FDA already dropped the hammer. Reproxalap got hit with another rejection because the agency says the evidence just isn’t consistent enough. Some trials looked good, others didn’t, and the FDA basically said the overall data doesn’t prove it works for dry eye. No safety issues, just a straight-up “we’re not convinced.” Market heard that and nuked the stock.
I’m watching for that grind back toward 4 to 5 as the dust settles and attention comes back. The crowd already ran. That’s where reversals like to start. Good time to load up.
